SLC5A2 and type 2 diabetes mellitus: The third is etrugliflozin L-PGA, which is a 1:1 cocrystal between etrugliflozin, another SGLT2 inhibitor, and L-pyroglutamic acid; it received FDA and EMA approvals in, respectively, 2017 and 2018 for the treatment of Type II diabetes (Steglatro® Tablets; Merck/Pfizer).